
Farber disease (FD) is a progressive lysosomal storage disorder caused by deficient acid ceramidase (ACDase) activity. Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) is also caused by biallelic variants of the ASAH1 gene, which encodes ACDase. ACDase deficiency leads to lysosomal accumulation of ceramide and the other lipids causing multi-system organ failure. Neurological involvement in FD patients is prominent. Some FD patients experience progressive neurological deterioration, ataxia, seizures, and developmental delays. SMA-PME patients develop progressive muscle weakness and seizures. There are no approved treatments for ACDase deficiencies; however, enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and HSCT-gene therapy (HSCT-GT) are being investigated. Previously we generated mouse models of both FD (P361R-FD) and SMA-PME (P361R-SMA) that recapitulate patient symptoms. The models have the same AsahI mutation but different background genotypes that lead to distinctive phenotypes. We show enhanced lifespans, increased body weights, and improved behavioral performances in both strains of ACDase deficient mice following lentivirus (LV)-mediated HSCT-GT employing syngeneic cells. Treatment normalized spleen and liver sizes and pathology, as well as peripheral blood characteristics including plasma MCP-1 and IL-6 levels. Moreover, LV-mediated HSCT-GT significantly reduced histiocytic infiltration and ceramide accumulation in the livers and brains of treated mice.